摘要
IFN-λ1是Ⅲ型干扰素家族的一个成员,具有与Ⅰ型干扰素相似的功能。此前,我们已经从毕赤酵母表达获得了可溶性重组人干扰素-λ1。然而,毕赤酵母表达中的高糖基化带来了免疫原性,影响了蛋白质的生产纯化效率。为了克服这个缺点,文中构建了一种干扰素突变体(rhIFN-λ1-Nm),定点突变潜在糖基化位点。AOX1启动子与α因子信号序列存在的情况下,用甲醇诱导成功地实现了rhIFN-λ1-Nm在毕赤酵母GS115胞外分泌表达。对rhIFN-λ1-Nm进行纯化,获得了纯度>98%的产品,并对糖化水平、分子量、二级结构、N末端序列等理化性质和生物活性进行了研究。研究结果表明,rhIFN-λ1-Nm糖基化水平明显降低,蛋白质生产纯化收率显著提高,而对结构和生物活性无影响;糖基化位点突变rhIFN-λ1可以被开发为IFN-λ1的替代品,有望发展成为未来的生物免疫制剂。
IFN-λ1 is a member of a new family of interferons called type Ⅲ IFNs with similar functions to type ⅠIFNs. Previously we obtained recombinant soluble human rhIFN-λ1 from Pichia pastoris. However, the hyper-glycosylation from P. pastoris brings immunogenicity and low purification recovery rate. To overcome this disadvantage, in this study, we constructed an rhIFN-λ1 mutant(rhIFN-λ1-Nm) devoid of the potential N-glycosylation sites by site-directed mutagenesis. rhIFN-λ1-Nm was successfully expressed and secreted extracellularly in P. pastoris(GS115) using methanol inducible AOX1 promoter with α-mating factor signal sequence. rhIFN-λ1-Nm was purified and characterized. There was no significant difference between rhIFN-λ1-Nm and rhIFN-λ1 in structure and bioactivity. The molecular weight was low after N-glycosylation mutation whereas the glycosylation was much lower. The mutational rhIFN-λ1(rhIFN-λ1-Nm) could legitimately be developed as substitutes for rhIFN-λ1, and thus it may be developed into a more promising therapeutic reagent in the future.
作者
惠希武
陈虹
黄秉仁
Xiwu Hui;Hong Chen;Bingren Huang(National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China;CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd., Shijiazhuang 050035, Hebei, China)
出处
《生物工程学报》
CAS
CSCD
北大核心
2018年第4期613-624,共12页
Chinese Journal of Biotechnology
基金
National Major Scientific and Technological Special Project for“Significant New Drugs Development”(No.2013ZX09402103)~~